Search by Drug Name or NDC
NDC 50474-0980-79 RYSTIGGO 140 mg/mL Details
RYSTIGGO 140 mg/mL
RYSTIGGO is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by UCB, Inc.. The primary component is ROZANOLIXIZUMAB.
MedlinePlus Drug Summary
Rozanolixizumab-noli is used to treat certain types of myasthenia gravis(MG; a disorder of the nervous system that causes muscle weakness). Rozanolixizumab is in a class of medications called Fc receptor blockers. It works by reducing the amount of IgG (an antibody that attacks neuromuscular receptors in patients with myasthenia gravis) circulating in the body.
Related Packages: 50474-0980-79Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Rozanolixizumab-noli
Product Information
| NDC | 50474-0980 |
|---|---|
| Product ID | 50474-980_7e1ada52-3db4-4e6b-9ec2-1c61cef0bd29 |
| Associated GPIs | |
| GCN Sequence Number | 085006 |
| GCN Sequence Number Description | rozanolixizumab-noli VIAL 280 MG/2ML SUBCUT |
| HIC3 | Z29 |
| HIC3 Description | NEONATAL FC RECEPTOR (FCRN) INHIBITORS |
| GCN | 54441 |
| HICL Sequence Number | 049035 |
| HICL Sequence Number Description | ROZANOLIXIZUMAB-NOLI |
| Brand/Generic | Brand |
| Proprietary Name | RYSTIGGO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ROZANOLIXIZUMAB |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 140 |
| Active Ingredient Units | mg/mL |
| Substance Name | ROZANOLIXIZUMAB |
| Labeler Name | UCB, Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761286 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 50474-0980-79 (50474098079)
| NDC Package Code | 50474-980-79 |
|---|---|
| Billing NDC | 50474098079 |
| Package | 1 VIAL, GLASS in 1 CARTON (50474-980-79) / 2 mL in 1 VIAL, GLASS |
| Marketing Start Date | 2023-06-26 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |